EVH · XBRL financial data

Evolent Health financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EVH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	925	908	—	—	—	—
Revenue from contracts with customers	1,022	908	1,352	1,964	2,555	1,876
Cost of revenue	—	658	1,035	1,503	2,187	1,476
Research and development	15	16	—	—	—	—
Selling, general and administrative	223	219	269	358	263	304
Total operating expenses	1,293	950	—	—	—	—
Other operating income (expense)	(0)	(0)	—	—	—	—
Operating income (loss)	(271)	(42)	4	(71)	(40)	(410)
Interest income	3	0	1	5	6	4
Interest expense	28	25	16	54	25	57
Other income (expense)	(0)	(0)	0	(1)	0	0
Income tax expense (benefit)	(4)	0	(43)	(89)	(1)	(0)
Net income (loss)	(334)	(38)	(19)	(113)	(62)	(535)
Earnings per share, basic USD per share	(3.94)	(0.44)	(0.20)	(1.28)	(0.81)	(5.07)
Earnings per share, diluted USD per share	(3.94)	(0.44)	(0.20)	(1.28)	(0.81)	(5.07)
Weighted average shares, basic millions of shares	85	86	94	111	115	114
Weighted average shares, diluted millions of shares	85	86	94	111	115	114

Fiscal years (EVH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	340	266	188	193	104	152
Accounts receivable	126	131	255	447	415	310
Prepaid and other current assets	61	51	21	30	29	19
Total current assets	546	524	478	684	607	506
Property and equipment, net	86	81	88	78	73	81
Right-of-use asset	58	50	49	12	6	4
Goodwill	355	426	723	1,117	1,137	694
Total assets	1,370	1,419	1,817	2,680	2,544	1,899
Accounts payable	32	96	57	48	96	60
Accrued liabilities	85	107	111	150	66	66
Current portion of long-term debt	27	0	—	—	—	—
Total current liabilities	402	445	433	674	716	385
Long-term debt	263	216	413	597	491	971
Lease liability, non-current	63	58	56	38	25	4
Total liabilities	751	726	958	1,434	1,353	1,484
Accumulated deficit	(589)	(627)	(606)	(719)	(781)	(1,315)
Total stockholders' equity	620	694	859	1,068	1,001	415
Total liabilities and equity	1,370	1,419	1,817	2,680	2,544	1,899
Common shares outstanding (cover page) millions of shares	86	91	111	115	117	112

Fiscal years (EVH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(334)	(38)	(19)	(113)	(62)	(535)
Stock-based compensation	15	17	34	41	40	40
Depreciation and amortization	61	60	67	123	118	116
Net cash from operating activities	(16)	39	(12)	143	19	39
Net cash from investing activities	261	(16)	(259)	(416)	(63)	(0)
Share repurchases	—	—	—	0	0	40
Proceeds from long-term debt	30	0	220	647	—	—
Repayments of long-term debt	—	98	0	464	0	—
Net cash from financing activities	(12)	(30)	132	281	(1)	(36)
Net change in cash	233	(7)	(140)	8	(45)	2

SIC 8741 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8741 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Evolent Health	116	653	(9.3)*	113.1M	12.4 quarters	Q2 FY26 10-QJun 30, 2026
Astrana Health	401	973	33*	55.7M	—	Q2 FY26 10-QJun 30, 2026
ICF International	4.6	474	100*	17.9M	—	Q2 FY26 10-QJun 30, 2026
Premier	43	240	16	82.7M	—	Q1 FY26 10-QSep 30, 2025
Onterris	13	187	6.2*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Huron Consulting Group	26	491	57*	15.8M	—	Q3 FY26 10-QSep 30, 2026
V2X	265	1,271	67*	31.4M	—	Q3 FY26 10-QOct 2, 2026
TSS	68	35	7.6*	28.2M	—	Q2 FY26 10-Q/AJun 30, 2026
Exponent	67	172	31*	47.5M	—	Q2 FY26 10-QJul 3, 2026

Not investment advice. Not affiliated with the U.S. SEC.